Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects

Fernando M Pimentel-Santos1,2,3*, Dário Ligeiro4, Mafalda Matos5, Ana F Mourão1,3, José Costa6, Helena Santos7, Anabela Barcelos8, Fátima Godinho9, Patricia Pinto10, Margarida Cruz11, João E Fonseca12,13, Henrique Guedes-Pinto2, Jaime C Branco1,3, Matthew A Brown14 and Gethin P Thomas14

Abstract

Introduction: A number of genetic-association studies have identified genes contributing to ankylosing spondylitis (AS) susceptibility but such approaches provide little information as to the gene activity changes occurring during the disease process. Transcriptional profiling generates a ‘snapshot’ of the sampled cells’ activity and thus can provide insights into the molecular processes driving the disease process. We undertook a whole-genome microarray approach to identify candidate genes associated with AS and validated these gene-expression changes in a larger sample cohort.

Methods: A total of 18 active AS patients, classified according to the New York criteria, and 18 gender- and age-matched controls were profiled using Illumina HT-12 whole-genome expression BeadChips which carry cDNAs for 48,000 genes and transcripts. Class comparison analysis identified a number of differentially expressed candidate genes. These candidate genes were then validated in a larger cohort using qPCR-based TaqMan low density arrays (TLDAs).

Results: A total of 239 probes corresponding to 221 genes were identified as being significantly different between patients and controls with a P-value <0.0005 (80% confidence level of false discovery rate). Forty-seven genes were then selected for validation studies, using the TLDAs. Thirteen of these genes were validated in the second patient cohort with 12 downregulated 1.3- to 2-fold and only 1 upregulated (1.6-fold). Among a number of identified genes with well-documented inflammatory roles we also validated genes that might be of great interest to the understanding of AS progression such as SPOCK2 (osteonectin) and EP300, which modulate cartilage and bone metabolism.

Conclusions: We have validated a gene expression signature for AS from whole blood and identified strong candidate genes that may play roles in both the inflammatory and joint destruction aspects of the disease.
appear specific for AS, whereas others have pleiotropic associations [5,6]. Nevertheless, the mechanism by which HLA-B27 and other more recently identified genetic factors involved in AS susceptibility, lead to disease remains uncertain.

Genetic studies provide little information as to the gene activity changes occurring during the disease process. Gene-expression profiling confers a “snapshot” of cellular activity providing information on mechanisms mediating disease changes, elucidating possible pathways involved and can also generate diagnostic gene sets. In AS and spondyloarthritis (SpA) a number of recent studies have defined transcriptional profiles generated from peripheral blood mononuclear cells (PBMCs) isolation requiring immediate sample processing, which is not suitable for larger multicentre studies and limits the viability of such an approach [7]. An alternate approach is to use whole blood samples collected using PAXgene technology which preserves the integrity of the RNA even with limited storage at room temperature allowing delays in transport and handling to occur with minimal RNA degradation [7].

In the current study, we undertook a whole-genome microarray approach to identify a genomic profiling in a Portuguese case-control collection, using RNA from peripheral blood collected using the PAXgene collection system, and validated these gene-expression changes in an independent larger sample cohort using quantitative PCR (qPCR). Our goal was to test whether genomic profiling in such cases, using the more practical PAXgene Blood RNA System®, could distinguish AS cases from healthy controls, and identify genomic pathways likely to be involved in AS pathogenesis.

Materials and methods

Study subjects

The microarray-based discovery study was performed using samples from 18 AS patients, diagnosed according to the modified New York criteria [8], and 18 gender- and age-matched healthy controls (±5 years). Included patients had Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores >4 and Bath Ankylosing Spondylitis Functional Index (BASFI) scores >4. All patients were receiving only NSAIDs and/or sulphasalazine. No TNF, corticoid or methotrexate treated patients were included. Details of the study subjects are shown in Supplementary Table S1 in Additional file 1.

Candidate genes were validated in a second larger cohort of another 78 AS patients and 78 age and sex matched controls (full details in Supplementary Table S2 in Additional file 2).

Peripheral blood samples were collected into PAXgene Blood RNA System® tubes (Qiagen, Doncaster, VIC, Australia) and stored according to the manufacturer’s recommendations [9]. This study was approved by the Ethics Committees of the participating centres, and written informed consent was obtained from the individuals involved in this study.

RNA processing and array analysis

Total RNA was extracted from whole blood samples according to the standard PAXgene protocol, quantified and the integrity assessed by Agilent 2100 BioAnalyser (Agilent, Santa Clara, CA, USA). Only samples with a RNA integrity number above 7.5 were used. To minimize the effects of Globin RNA transcript over-representation, samples were processed with Ambion GLOBINclear® (Applied Biosystems, Mulgrave, VIC, Australia) according to the manufacturer’s protocol. cRNA was generated from 500 ng of total RNA using the Illumina TotalPrep cRNA Amplification Kit® (ABI) and hybridized to Human HT-12 V3 Expression BeadChips (Illumina, San Diego, CA, USA). Array data were processed using the Illumina GenomeStudio software, transformed by variance stabilization transformation (VST) [10] and normalized by robust spline normalization [11] using Lumi [12]. Quality control using principal components analysis showed four samples to be outliers and further investigation revealed technical issues with the processing of these samples and thus they were excluded from the analysis.

Gene expression analysis was performed in BRB-ArrayTools [13]. Differentially expressed genes were identified by unpaired t-test with multivariate permutation correction. Gene ontology analysis was carried out in BRB ArrayTools using a LS permutation test which finds gene sets that have more genes differentially expressed among the classes than it would be expected by chance using 100,000 random geneset permutations to compare to the chosen geneset.

Candidate gene validation using quantitative reverse transcription polymerase chain reaction

Candidate genes were identified from the array studies based upon their fold-change between AS and control, the P-value of this difference and their potential biological relevance to AS. Candidate genes were assayed using real-time quantitative PCR-based (qPCR) predesigned TaqMan Low Density Array Cards (TLDAs). The TDA cards had 48 predesigned Taqman qPCR assays, which utilise MGB probes with FAM dye, arrayed in a 384-well format allowing four samples to be assayed per TDA. Forty-seven candidate genes selected from the whole genome arrays together with a housekeeping gene (18s) were arrayed. cDNA was generated from 1 µg of total RNA using the Bioline cDNA synthesis Kit (Bioline, London, UK) according to manufacturer’s instructions. qPCR was carried out using SensiMix dT
RT-PCR reagent (Quantace, Sydney, QLD, Australia) under the following conditions; 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 s and 60°C for 60 s [14].

Data were normalized using the housekeeping gene, 18S, included on the card and quantified using the 2$^-^{ΔCT}$ [15]. Data were analysed with the Mann-Whitney test and \( P \)-values <0.05 were considered significant (SPSS v17.0, Chicago, IL, USA).

Results

Differential gene expression in AS patients and controls

From a total of more than 48,000 probes on the array, 18,159 were found to be expressed in at least one sample and were included for analysis. To estimate the degree of gene expression variation driven by disease status, we undertook unsupervised hierarchical clustering using the top 3% most variably expressed genes without reference to disease status. Clustering with this non-biased geneset gave good delineation between the controls and AS patients with only six controls and five AS patients misclassifying (Figure 1). To identify the genes specifically differentially expressed between patients and controls, we carried out an unpaired T-test corrected for multiple comparisons. A total of 648 probes were considered significantly expressed (80% confidence level of false discovery rate, with 10% false positives) with 204 of these probes (corresponding to 190 genes) having \( P \)-values <0.0005 (Supplementary Table S3 in Additional file 3). The magnitude of differential expression observed was generally low, with only three genes showing a significant fold-change >2 (with the maximum fold-change being 2.21) and 29 genes >1.5 fold-change. Of the 204 probes, 89 probes were upregulated and 115 downregulated. Our microarray data are available in a public repository, Gene Expression Omnibus (GEO), with the accession number [GEO:GSE25101].

We then selected 47 of the differentially expressed genes for validation by qPCR (Table 1) based upon their \( P \)-value, fold-change and biological relevance.

Quantitative RTPCR validation

Expression levels of the 47 selected genes were confirmed by qPCR in a second sample set consisting of 78 patients and 78 age and gender matched controls. A total of 28 of the 47 genes showed a similar trend in differential expression between AS and control samples as the array data. Of these, 14 of the 47 considered genes were validated with significant \( P \)-values with 13 downregulated 1.4 to 2.2-fold and only 1 upregulated (1.6-fold) (Table 2).

Gene ontology analysis

Gene ontology (GO) analysis on the dataset showed two key immune-associated pathways to be altered, “negative regulation of adaptive immune response” and several ontologies affecting “thymic T cell selection” both with \( P \)-values <0.005 (Table 3).

Discussion

Gene expression profiling in disease reveals the underlying gene activity changes contributing to the disease process. This information provides insight into the tissue changes during the disease development and enables targets for therapeutic intervention to be identified. Second, strong, consistent gene expression changes can be utilized to generate diagnostic algorithms to identify early-stage disease before significant tissue damage has occurred.

However, in SpA, and in AS in particular, only a small number of case-control genomic profiling studies have been undertaken. The early studies involved low sample numbers and poor genome coverage and were very heterogeneous in terms of methodology, including the source of mRNA studied [16-19]. More recently four studies using genome-wide microarrays showed interesting results regarding SpA physiopathology and biomarker identification [20-23]. Of these, two were PBMC based [20,21] and in two the RNA was isolated from unfractionated peripheral blood [22,23]. However, all these studies did confirm that AS/SpA cases could be reliably distinguished from healthy controls using genomic profiling [20-23].

Although PBMCs have been widely used in autoimmune disease gene expression profiling studies, PBMCs do not represent an ideal tissue source for larger scale multicentre studies requiring extensive downstream processing soon after collection. PAXgene tubes enable whole blood to be collected directly into an RNA-preservation which stabilises the RNA from degradation for up to three days at room temperature, long enough for
the samples to reach a safe frozen depository [9]. However, differences in the transcriptional profile between PBMC and PAXgene derived RNA have been demonstrated. These differences are due to the different cell populations targeted as well as the extra processing steps required for PAXgene samples to prevent globin mRNA overrepresentation affecting microarray sensitivity [9,24]. The study reported here has a number of strengths in that it represents a multicenter study involving ethnically homogeneous patients with AS (defined according to the modified New York criteria) and excluded patients on anti-TNF agents. Use of a primary dataset for candidate gene identification (by microarrays) followed by validation by qPCR in an independent dataset provides additional robustness.

Using the most variably expressed genes for unsupervised clustering gave us an estimate of the proportion of the gene expression variation driven by disease status. That only six controls and five AS samples were misclassified indicates the major driver of gene expression as disease status. However, the fact that not all samples classified correctly also indicates other factors driving gene expression variation. Such factors may be differences in blood collection, storage and transport protocols that can arise in multicentre studies. However, none of these effects were robust enough to cluster independently when tested (data not shown).

We validated 14 differentially expressed genes between AS patients and healthy controls. A number of these genes have well-documented inflammatory roles or an action on bone/cartilage metabolism. Moreover, GO analysis showed two key immune-associated pathways to be altered, “negative regulation of adaptive immune

---

**Table 1 Selected genes for validation by qPCR**

| Gene symbol | Fold-change (AS/Cont) | Parametric P-value |
|-------------|-----------------------|--------------------|
| CX3CR1      | 0.58                  | 3.45E-04           |
| DGKQ        | 0.62                  | 1.45E-05           |
| SPOCK2      | 0.65                  | 3.07E-04           |
| SBK1        | 0.66                  | 1.69E-04           |
| GZMM        | 0.67                  | 3.39E-04           |
| CDC25B      | 0.67                  | 2.00E-04           |
| CLSTN1      | 0.68                  | 4.53E-04           |
| ITGB7       | 0.68                  | 5.63E-04           |
| PTPN1       | 0.69                  | 1.50E-06           |
| EP300       | 0.70                  | 1.26E-04           |
| DOCK10      | 0.70                  | 1.73E-04           |
| MAPK8P3     | 0.70                  | 3.37E-04           |
| BCL11B      | 0.70                  | 5.88E-04           |
| DNM1T1      | 0.71                  | 6.46E-05           |
| XPC         | 0.71                  | 5.10E-06           |
| PPP2R1A     | 0.71                  | 1.73E-04           |
| IL27RA      | 0.72                  | 4.40E-06           |
| MCM3        | 0.73                  | 4.24E-04           |
| SYF2        | 1.34                  | 5.94E-04           |
| PPP2R3C     | 1.36                  | 1.07E-03           |
| NGRAP1      | 1.37                  | 1.87E-04           |
| ZMAT2       | 1.38                  | 1.58E-04           |
| MYL6        | 1.41                  | 7.94E-05           |
| S100A8      | 1.43                  | 6.09E-04           |
| GMPG        | 1.43                  | 3.91E-05           |
| VAMP5       | 1.44                  | 4.21E-04           |
| CCLF        | 1.46                  | 4.30E-04           |
| SHFM1       | 1.47                  | 8.62E-04           |
| ATG3        | 1.49                  | 6.10E-04           |
| MRPS18C     | 1.49                  | 5.71E-04           |
| CLEC4D      | 1.52                  | 3.47E-04           |
| UBL5        | 1.52                  | 8.93E-05           |
| AIF1        | 1.52                  | 5.19E-04           |
| PDCD10      | 1.54                  | 2.45E-03           |
| NDUF54      | 1.54                  | 5.93E-04           |
| SF3B14      | 1.54                  | 2.39E-04           |
| HMG2        | 1.57                  | 3.41E-04           |
| UQCRB       | 1.63                  | 2.33E-04           |
| TXN         | 1.68                  | 4.39E-05           |
| CMTM2       | 1.74                  | 4.78E-04           |
| CIP29       | 1.75                  | 1.38E-04           |
| CHMP5       | 1.78                  | 6.80E-04           |
| PSMA4       | 1.80                  | 8.45E-05           |
| NDUF83      | 1.88                  | 1.25E-04           |
| LSM3        | 1.99                  | 6.72E-04           |
| GNG11       | 2.15                  | 1.41E-04           |
| CCDC72      | 2.21                  | 9.64E-05           |

**Table 2 Validated genes by qRTPCR**

| Parametric P-value | Fold-change | Gene symbol |
|--------------------|-------------|-------------|
| 2.90E-06           | 0.4457398   | BCL11B      |
| 1.30E-06           | 0.4597414   | DNM1T1      |
| 2.50E-06           | 0.5009603   | CDC25B      |
| 1.94E-05           | 0.5214546   | CLSTN1      |
| 0.008539           | 0.5323253   | VAMP5       |
| 1.81E-05           | 0.5435122   | DOCK10      |
| 0.0005221          | 0.5693345   | SPOCK2      |
| 0.0012085          | 0.5831974   | ITGB7       |
| 0.001398           | 0.6124764   | MCM3        |
| 0.026755           | 0.6632639   | CX3CR1      |
| 0.0026443          | 0.6749132   | PTPN1       |
| 0.0034889          | 0.6847808   | EP300       |
| 0.0125026          | 0.7141221   | PPP2R1A     |
| 0.0184087          | 1.6090812   | CLEC4D      |

Of the 47 considered genes, 14 were validated with significant P-values (P <0.05). q-RTPCR, quantitative reverse transcription polymerase chain reaction.

Genes (n = 47) for validation by qPCR were selected from the 648 probes significantly differentially expressed in microarrays based upon their P-value, fold-change and biological relevance. AS, Ankylosing spondylitis; qPCR, quantitative polymerase chain reaction.
response” and several ontologies affecting “thymic T cell selection”. Interestingly the GO analysis indicated a “negative” regulation of the immune system. This agrees with a previous expression profiling recently reported in PBMCs from AS patients [20] and is also consistent with the “reverse IFN gamma signature” reported by another group studying macrophages from AS patients [19].

A possible reduced immune response also correlates with the downregulation of PTPN1 and DOCK10, which are both involved in mediating IL4 actions [25]. Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed enzyme shown to negatively regulate multiple tyrosine phosphorylation-dependent signalling pathways, including IL4 signalling [26]. Dock10 is also regulated by IL4 in B cells [27]. This is of particular interest as IL4 may play a role in AS pathogenesis. Interleukin 4 (IL4), a 20-kDa product from activated T lymphocytes, has a variety of stimulatory and inhibitory actions on B and T cells [25,28-30]. Recent studies have also indicated a potential role for IL4 producing CD8⁺ T cells in the pathogenesis of AS. Although CD8⁺ T cells are predominately associated with the production of Th1 cytokines, such as IFNgamma, there is now good evidence that some subsets of these cells can also produce ‘Th2’ cytokines such as IL4, IL5 and IL10 [31]. The potential functions associated with IL4-producing CD8⁺ T cells are as yet unclear but the subtype CD8⁺/TCR alpha beta + T cells, with a regulatory phenotype and function (expressing CD25+, CTLA4+, Foxp3+, but negative for IFNgamma and perforin), were previously described in peripheral blood of AS patients [32]. These results were confirmed in a recent study suggesting an altered pattern of CD8⁺ T cell differentiation in AS and in HLA-B27⁺ healthy individuals [33]. This predisposition to generate IL4⁺CD8⁺ T cells may play a role in pathogenesis of SpA [32,33].

In addition, the activation of the innate immune system has been proposed to play an important role in AS inflammation. Dysregulation of Toll-like receptor (TLR)-related pathways (an upregulation of TLR4 and TLR5), involved in innate immune response, have been described [23]. Interestingly we also identified increased expression of TLRs 4 and 5, together with TLR1 but the significance was marginal and, therefore, not followed up. However, an upregulation of C-type lectin domain family 4, member D (CLEC4D), another gene involved in the innate immune response, was seen. CLEC4D has been found to be expressed in a monocyte/macrophage restricted manner, and although no ligand or biological function has as yet been described, the receptor has been shown to be upregulated at the transcript level in a number of disease settings, similarly to two others members of the family, Mincl and Dectin-2. They are able to recognize and promote pathogen clearance and induce inflammatory signals [34]. This process seems to follow the Syk and caspase recruitment domain protein (CARD9) pathway which was recently implicated in a mouse model of SpA [35].

Changes in SPOCK2 (osteonectin) and EP300 provide interesting insights into AS progression. SPOCK2, also known as Sparc/osteonectin, was implicated, in a recent study, as a discriminator between SpA and healthy controls [22] and has been hypothesised to play roles in the regulation and production, assembly, or maintenance of matrix turnover in cartilage [36,37]. In this process TGFβ and IFNgamma exert antagonistic effects, and play important roles in the physiologic regulation of extracellular matrix turnover. TGFbeta positively regulates COL1A2 through the cellular Smad signal transduction pathway, contrary to IFNgamma which downregulates COL1A2 through Stat1. Interestingly, the protein produced by EP300 belongs to the group of nuclear p300/CBP transcriptional coactivators for both Smad3 and Stat1a, and integrates signals that positively or negatively regulate COL1A2 transcription [38]. In addition, the downregulation of EP300 may promote a pro-inflammatory status [39] contributing to cartilage degradation. The protein phosphatase 2, regulatory subunit A (PPP2R1A) has also been shown to play a role in TGFβ-mediated regulation of Smad3-activated genes [40]. Finally, transactivated p300, controlled by phosphoinositide-3 kinase (PI3K)/AKT, is an important transcriptional co-activator of Sox9 [41], which modulates the expression of the major extracellular matrix component, aggrecan. Not surprisingly, altered EP300 expression has been associated with the Wnt pathway, a key mediator of bone formation as well as cartilage

### Table 3 Gene ontology analysis

| GO category | GO ontology | GO term | LS permutation | P-value |
|-------------|-------------|---------|----------------|---------|
| GO:0002820  | BP          | Negative regulation of adaptive immune response | 0.000001 |
| GO:0033077  | BP          | T cell differentiation in the thymus | 0.000001 |
| GO:0043383  | BP          | Negative T cell selection | 0.000001 |
| GO:0045061  | BP          | Thymic T cell selection | 0.000001 |

The dataset showed two key immune-associated pathways to be altered, “negative regulation of adaptive immune response” and several ontologies affecting “thymic T cell selection” both with P-values <0.005.
alterations in osteoarthritis [42]. Downregulation of these genes might lead to a loss of matrix integrity thereby accelerating tissue damage. PTP1B has also been shown to induce apoptosis in chondrocytes, thus downregulation might result in increased chondrocyte numbers contributing to joint damage as has been seen in osteoarthritis [43]. Both EP300 and DNA (cytosine-5-)-methyltransferase 1 (DNMT1), mediate STAT3 functionality [44] which has also been associated in genetic studies with AS [45]. Decreases in STAT3 signalling might also contribute to the hypothesised reduction in immune response [46].

CX3CR1, which plays a pro-inflammatory role in RA, was also downregulated. In RA, CX3CR1, and its ligand CX3CL1, drives chemotaxis of pro-inflammatory monocytes to inflammatory sites [47]. Decreased expression of this gene in AS may reflect the fundamental differences in disease processes between AS and RA.

Beta 7 integrins have been shown to play a role in chronic ileitis [48,49] a common clinical feature of SPA. In our study, beta 7 integrin (ITGB7) is under-expressed again possibly reflecting a decreased immune response in AS.

The specific function of several other genes, as BCL11B, CDC25B, VAMP5, MCM3, CLSTN1 have not yet been determined and their potential involvement in disease processes needs additional research.

Conclusions

We have validated a gene expression signature for AS from whole blood and identified strong candidate genes that may play roles in both the inflammatory environment and bone and cartilage effects. Future studies are needed to confirm some of the possible interactions suggested by this study.

Additional material

Additional file 1: Supplementary Table S1: Characteristics of subjects involved in microarrays study. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; PBMCs, peripheral blood mononuclear cells; qPCR, quantitative polymerase chain reaction; q-RTPCR, quantitative reverse transcription polymerase chain reaction; SpA, spondyloarthritis; TLDA, TaqMan Low Density Array Cards.

Additional file 2: Supplementary Table S2: Characteristics of subjects involved in TLDA study. AS (n = 78) and healthy controls (n = 78). No significant differences for age and sex between groups.

Additional file 3: Supplementary Table S3: Genes differentially expressed between AS patients and controls by microarrays. A total of 648 probes were considered significantly differentially expressed (80% confidence level of false discovery rate with 10% false positives).

Abbreviations

AS: ankylosing spondylitis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; GO: gene ontology; mSASSS: modified Stoke Ankylosing Spondylitis Spinal Score; PBMCs: peripheral blood mononuclear cells; qPCR: quantitative polymerase chain reaction; q-RTPCR: quantitative reverse transcription polymerase chain reaction; SpA: spondyloarthritis; TLDA: TaqMan Low Density Array Cards.

Acknowledgements

We would like to thank the individuals who shared their clinical data with us to complete this study, to ANEA (Ankylosing Spondylitis Portuguese Patients Association) and all team of CORPOREA Study Group. This study was supported by for Bolsa de Investigación de la Sociedad Portuguesa de Reumatología/Scherin-Pleugh 2007, FCML 2007 Grant, and Wythe Lederle Portugal Grant. MAB is supported by a National Health and Medical Research Council (Australia) Principal Research Fellowship. GT is funded by a Lions Medical Research Foundation Fellowship. CORPOREA Study Group: Centro Hospitalar de Lisboa Oriental, Hospital de Egas Moniz, Lisboa: AF Moutão, AA de Matos, C Ribeiro, FM Pimentel-Santos, J Bravo Pimentão, J C Branco, M M Mateus, P Nero, P Araújo, S Faria, TL Pinto, W Castelão. Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa: E Vieira de Sousa, J Caetano-Lopes, JE Fonseca. Instituto Português de Reumatologia, Lisboa: C Silva, E Simões, H Madeira, H Santos, J Vaz Patto, J Ferreira, M Micaielo, MJ Medaliavila, M Sousa. Hospital Curry Cabral EPE, Lisboa: P Soares Branco, Hospital Garcia de Orta EPE, Almada: F Godinho, J Canas da Silva, S Garcés, V Tavares. Centro Hospitalar do Alto Minho, Hospital Conde de Beritandes EPE, Ponte de Lima: A Ribeiro, D Araújo, JA Costa, L Costa, MC Afonso, M Bogas, S Alcino. Centro Hospitalar de Vila Nova de Gaia/ Espinho EPE, Vila Nova de Gaia: P Pinto. Hospital Central de Faro EPE, Faro: AR Cravo, G Sequeira. Hospital Militar Principal, Lisboa: RA Santos. Centro Hospitalar Baixo Vouga, Hospital Infantile D. Pedro EPE: A Barcelos, I Cunha. Centro Hospitalar Oeste Norte, Centro Hospitalar das Caldas da Rainha. M Cruz.

Author details

1 CEDOC, Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Campo de Mântes da Pátria, n° 130, 1169-036 Lisboa, Portugal. 2 Instituto de Biotecnologia e Bioengenharia, Centro de Genómica e Biotecnologia, da Universidade de Trás-os-Montes e Alto Douro (IBB/CBG - UTAD), Quinta dos Prados, 5000-262 Vila Real, Portugal. 3 Centro Hospitalar Lisboa Ocidental (CMLCO), Hospital de Egas Moniz EPE, Rua da Beneficência, n° 126, 1769-019 Lisboa, Portugal. 4 Centro de Histocompatibilidade do Sul, Alameda das Linhas de Torres, n° 117, 1769 - 001 Lisboa, Portugal. 5 Universidade de Trás-os-Montes e Alto Douro, Quinta dos Prados, 5000-262 Vila Real, Portugal. 6 Centro Hospitalar do Alto Minho (CHAM), Hospital Conde de Beritandes EPE, Largo Conde de Beritandes, 4990-041 Ponte de Lima, Portugal. 7 Instituto Português de Reumatologia (IPR), Rua da Beneficência, n° 7, 1050-034 Lisboa, Portugal. 8 Centro Hospitalar Baixo Vouga, Hospital Infantile D. Pedro EPE, Avenida Artur Ravara, 3814-501 Aveiro, Portugal. 9 Hospital Garcia de Orta EPE, Av. Torrado da Silva, Pragal, 2801-951 Almada, Portugal. 10 Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Rua Dr. Francisco Sá Carneiro, 4400-129 Vila Nova de Gaia, Portugal. 11 Centro Hospitalar Oeste Norte, Centro Hospitalar das Caldas da Rainha, Rua Diário de Notícias, 2500-176 Caldas da Rainha, Portugal. 12 Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular (IMM), Faculdade de Medicina da Universidade de Lisboa, Edifício Egas Moniz, Av. Professor Egas Moniz, 1649-035 Lisboa, Portugal. 13 Centro Hospitalar de Lisboa Norte, Hospital Santa Maria EPE, Av. Professor Egas Moniz, 1649-035 Lisboa, Portugal. 14 University of Queensland Diamantina Institute, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia.

Authors’ contributions

FMPS and GT participated in the conception and design of the study, carried out the lab work, performed the data analysis and drafted the manuscript. DL, HGP, JCB and MAB participated in the conception and design of the study and critically revised the manuscript. JEF critically revised the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.
References

1. Schett G: Bone formation versus bone resorption in ankylosing spondylitis. *Adv Exp Med Biol* 2009, 649:114-121.

2. Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Sharif A, Taylor A, Calin A, Wordsworth P: Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. *Arthritis Rheum* 1997, 40:1823-1828.

3. Hammersma J, Cardon LR, Bradbury L, Brophy S, van der Horst-Bruinsma I, Calin A, Brown MA: Is disease severity in ankylosing spondylitis genetically determined? *Arthritis Rheum* 2001, 44:1206-1400.

4. Brophy S, Hickey S, Menon A, Taylor G, Bradbury L, Hammersma J, Calin A: Concordance of disease severity among family members with ankylosing spondylitis? *J Rheumatol* 2004, 31:1775-1779.

5. Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton Pr, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy M, Ouwerkerk KH, Samani NJ, Todd JA, Donnelly P, Barrett JC, Davidson D, Easton D, Evans DM, Leung HT, Martini E, Morris AP, Spencer CC, Tobin MD, Atwood AP, Boorman JP, Cant B, Evison U, Hussey JM, Jolley JD, Knight AS, et al: Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autismomy variants. *Nat Genet* 2007, 39:1329-1337.

6. Briozzo LF, Revellie JD: The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis. *Curr Opin Rheumatol* 2008, 20:384-391.

7. Debye S, Schenbenck U, Hellmich M, Garthoff BS, Pillai R, Zander T, Schultze JL: Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. *Pharmacogenomics* 2004, 5:1493-207.

8. van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984, 27:361-368.

9. Kruhoffer M, Dyrskjot L, Voss T, Lindberg RL, Wynich R, Thykaer T, Omtvoll TF: Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAxgene blood RNA tube. *J Mol Diagn* 2007, 9:452-458.

10. Lin SM, Du P, Huber W, Kibbe WA: Model-based variance-stabilizing transformation for Illumina microarray data. *Nucleic Acids Res* 2008, 36:e11.

11. Workman C, Jensen LJ, Harmer J, Bork R, Gaaster L, Nielsen HB, Saxild HH, Nielsen C, Bruun SN, Knudsen S: A new non-linear normalization method for reducing variability in DNA microarray experiments. *Genome Biol* 2002, 3:research0048.

12. Du P, Kibbe WA, Lin SM: Lucid: a pipeline for processing Illumina microarray. Bioinformatics 2008, 24:1547-1548.

13. Simon R, Lam A, Li MC, Nagan M, Meenaz S, Zhao Y: Analysis of Gene Expression Data Using BRB-Array Tools. *Cancer Inform* 2007, 31:17-11.

14. Steg A, Wang W, Blanquicett C, Darke C, Duncan E, Sharif A, Taylor G, Bradbury L, Hammersma J, Calin A: Concordance of disease severity among family members with ankylosing spondylitis? *J Rheumatol* 2004, 31:1775-1779.

15. Simon R, Lam A, Li MC, Nagan M, Meenaz S, Zhao Y: Analysis of Gene Expression Data Using BRB-Array Tools. *Cancer Inform* 2007, 31:17-11.

16. Gu J, Wei YL, Wei JC, Huang F, Jian MS, Centola M, Frank MB, Yu D: Identification of RG51 as a candidate biomarker for undifferentiated spondylarthritides by genome-wide expression profiling and real-time polymerase chain reaction. *Arthritis Rheum* 2009, 60:3269-3279.

17. Sharma SM, Choi D, Planck SR, Harrington CA, Austin CR, Lewis JA, Diebel TN, Martin TM, Smith JR, Rosenbaum JT: Insight into the pathogenesis of axial spondyloarthritis based on gene expression profiles. *Arthritis Res Ther* 2009, 11:R168.

18. Sassasi S, Revellie JD, Annet FC, Weismann MH, Ward WM, Agarwal SK, Gourh P, Bhula J, Shafi R, Sampat K, Mayes MD, Tan FK: Whole-blood gene expression profiling in ankylosing spondylitis shows upregulation of Toll-like receptor 4 and 5. *J Rheumatol* 2010, 38:87-99.

19. Vatanian K, Stoltte R, Johnstone T, Casale A, Planck SR, Choi D, Smith JR, Rosenbaum JT, Harrington CA: Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis. *BMC Genomics* 2009, 10:2.

20. Paul WE, Ohara J: B-cell stimulatory factor-1/Interleukin 4. *Annu Rev Immunol* 1987, 5:429-459.

21. Lu X, Malumbres R, Shields B, Jiang X, Sarosiak J, Natkunam Y, Tiganis T, Losos P: PTBP1 is a negative regulator of interleukin 4-induced STAT6 signaling. *Blood* 2008, 112:4098-4108.

22. Yelo E, Bernardo MW, Gennaro L, Alcaraz-Garcia MJ, Majado MJ, Parrado A, Dock10, a novel C2H protein selectively induced by interleukin-4 in human B lymphocytes. *Mol Immunol* 2008, 45:3411-3418.

23. O’Garra A, Ullman S, De France T, Christiansen J: ‘B-cell factors’ are pleiotropic. *Immunol Today* 1988, 9:45-94.

24. Jelinek DF, Lipsky PE: Inhibitory influence of IL-4 on human B cell responsiveness. *J Immunol* 1988, 141:164-173.

25. Rouset F, Malefiet RJ, Sierensregt B, Aubry JP, Bonnelfoy Y, Defrance T, Banchereau J, de Vries JF: Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt’s lymphoma cell lines by human IL-4 and IFN-gamma. *J Immunol* 1988, 140:2625-2632.

26. Baik HJ, Zhang L, Jarvis LB, Gaston JS. Increased IL-4+ CD8+ T cells in peripheral blood and autoreactive CD8+ T cell lines of patients with inflammatory arthritis. *Rheumatology* 2008, 47:795-803.

27. Jarvis LB, Matsuzak M, Duggleby RC, Goodall JC, Hall FC, Gaston JS. Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function. *Eur J Immunol* 2005, 35:2896-2908.

28. Zhang L, Jarvis LB, Baik HJ, Gaston JS. Regulatory IL4+CD8+ T cells in patients with ankylosing spondylitis and healthy controls. *Ann Rheum Dis* 2009, 68:1346-1351.

29. Graham LM, Brown GD: The Dec2-2 family of C-type lectins in immunity and homeostasis. *Cytokine* 2009, 48:148-155.

30. Ruetu M, Yadav B, Thomas G, Steck R, Strutton G, Tran A, Velasco J, Degilla Esposti M, Zinkernagel M, Brown M, Thomas R. Fungal beta-glucan triggers spondyloarthropathy and Crohn’s disease in SKG mice. *Arthritis Rheum* 2010, 62 Suppl 10:1446.

31. Hausser HJ, Deckling R, Brenner RE: Testican-1, an inhibitor of pro-MMP-2 activation, is expressed in cartilage. *Osteoarthritis Cartilage* 2004, 12:870-877.

32. Gruber HE, Sage EH, Norton HJ, Funk S, Ingram J, Hanley EN Jr: Targeted deletion of the SPARC gene accelerates disc degeneration in the aging mouse. *J Histocem Cytochem* 2005, 53:1131-1138.

33. Ghosh AK, Yuan W, Mori Y, Chen SJ, Varga J: Antagonistic regulation of type I collagen gene expression by interleukin-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. *J Biol Chem* 2001, 276:11041-11048.

34. Ahmad R, Qureshi HY, El Mabrouk M, Sylvester J, Ahmad M, Zafarullah M. Inhibition of interleukin-1-induced matrix metalloproteinase 13
expression in human chondrocytes by interferon gamma. Ann Rheum Dis 2007, 66:782-789.
40. Heikkinen PT, Nummela M, Leivonen SK, Westermark J, Hill CS, Kahari VM, Jaakkola PM: Hypoxia-activated Smad3-specific dephosphorylation by PP2A. J Biol Chem 2010, 285:3740-3749.
41. Cheng CC, Uchiyama Y, Hiyama A, Gaigahate S, Shapiro IM, Rosbud MV: PI3K/AKT regulates aggrecan gene expression by modulating Sox9 expression and activity in nucleus pulposus cells of the intervertebral disc. J Cell Physiol 2009, 221:668-676.
42. Velasco J, Zarrabeitia MT, Prieto JR, Perez-Castrillon JL, Perez-Aguilar MD, Perez-Nuñez MJ, Salutaro C, Hernandez-Elena J, Calvo I, Omis F, Gonzalez-Macias J, Rancho JA: Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study. Osteoporos Int 2010, 21:109-118.
43. Gagarina V, Gabay O, Dvir-Ginzberg M, Lee EJ, Brady JK, Quon MJ, Hall DJ: SirT1 enhances survival of human osteoarthritic chondrocytes by repressing protein tyrosine phosphatase 1B and activating the insulin-like growth factor receptor pathway. Arthritis Rheum 2010, 62:1383-1392.
44. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Waski MA: STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA 2005, 102:6948-6953.
45. Davidson SI, Liu Y, Danoy PA, Wu X, Thomas GP, Jiang L, Sun L, Wang N, Han J, Han H, Australo-Anglo-American Spondyloarthritis Consortium; Vischer FM, Brown MA, Xu H: Association of STAT3 and TNFRSF1a with ankylosing spondylitis in Han Chinese. Ann Rheum Dis 2011, 70:289-292.
46. Quantron LJ, Mageer JP: NF-xB and STAT3 signaling hubs for lung innate immunity. Cell Tissue Res 2011, 343:153-165.
47. Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K, Hayashi K, Hasegawa J, Yoshida O, Miyagishi N: Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:2878-2883.
48. Rivera-Nieves J, Olson T, Bamias G, Bruce A, Solga M, Knight RF, Ciminelli F, Ley K: L-selectin, α4β7, and α4β1 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. Expanding. J Immunol 2005, 174:2343-2352.
49. Gorfu G, Rivera-Nieves J, Hoang S, Abbott DW, Arbenz-Smith K, Azar DW, Pizarro TT, Ciminelli F, McQuille M, Ley K: Beta7 integrin deficiency suppresses B cell homing and attenuates chronic ileitis in SAMP1/HtFc mice. J Immunol 2010, 185:5561-5568.

doi:10.1186/ar3309
Cite this article as: Pimentel-Santos et al.: Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects. Arthritis Research & Therapy 2011 13:R57.